Skip to Late-Breaking Abstracts »
All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).
Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.
ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.
# | Type | Title | Authors | Category | Keywords | |
---|---|---|---|---|---|---|
97 | Poster Presentation | High throughput screening of HPV-antigen peptides and expansion of tumor-specific T cells for adoptive cell therapy of HPV-associated malignancies | David Langan, PhD; Jourdain Lemaster; Lauren Suarez, PhD; Pratima Kunwar, PhD; Sojung Kim, PhD; Mathias Oelke, PhD | Cellular Therapies | Adoptive immunotherapy;T cell;Tumor antigens | |
98 | Poster Presentation | NX-0255, a small molecule CBL-B inhibitor, expands and enhances tumor infiltrating lymphocytes (TIL) for use in adoptive cancer immunotherapy | Sarah Whelan, PhD; Jennifa Gosling, MSc; Monisha Mani, MSc; Frederick Cohen, PhD; Austin Tenn-McClellan, BS; Janine Powers, PhD; Gwenn Hansen, PhD; Michael T. Lotze, MD; Arthur T. Sands, MD, PhD | Cellular Therapies | Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
99 | Poster Presentation | T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants | Daniel Hirschhorn, PhD; Sadna Budhu, PhD; David Schröder, MD, PhD; Lukas kraehenbuehl; Anne-Laurent Flammar; Andrew Chow, MD, PhD; Isabell Schulze; Sara Schad, BS; Jacob Ricca; Billel Gasmi; Olivier De Henau; Levi M. Mangarin, BS; David Redmond; Czrina Cortez, BS; Cailian Liu, MD; Aliya Holland; Mathieu Gigoux, PhD; Asrhi Arora; Katherine S. Panageas, PhD; Gabrielle Rizzuto; Jean Albrengues, PhD; Mikala Egeblad, PhD; Jedd D. Wolchok, MD/PhD; Taha Merghoub, PhD | Cellular Therapies | Adoptive immunotherapy;Checkpoint blockade;Costimulation;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
100 | Poster Presentation | Redirecting glucose flux during in vitro expansion improves the in vivo performance of adoptive T cell therapies for cancer | Andrew Frisch, BS; Yupeng Wang, BD; Yiyang Wang, N/A; Konstantinos Lontos, MD; Dayana Rivadeneira, PhD; Greg M. Delgoffe, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
101 | Poster Presentation | Expansion of tumor-infiltrating lymphocytes (TIL) using static bag for the clinical manufacturing rapid expansion protocol (REP) process | Kenneth Onimus; Adrian Wells; Nermin Gerges; Courtney Herman; Shwetha Lakshmipathi; Viktoria Gontcharova, PhD; Joe Wypych; Arvind Natarajan; Anand Veerapathran | Cellular Therapies | Adoptive immunotherapy;Neoantigens;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
102 | Poster Presentation | The deep phenotype characterization of “Off-the-Shelf” CD19-Chimeric Antigen Receptor (CAR) T Cells allows to identify their subset complexity and to optimize their manufacturing | Cristina Maccalli, PhD; Asma Al-Sulaiti; Mohammed El-Anbari, PhD; Moza Al Khulaifi, BSc; Mohammed Toufiq; Rebecca Mathew; Chiara Cugno, MD; Sara Deola, MD; Suruchi Mohan, MD; Damilola Olagunju; Chiara Bonini, MD; Monica Casucci, PhD; Sara Tomei, PhD; Damien Chaussabel, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;T cell lineages | |
103 | Poster Presentation | Quality improvement of anti-CD38-JAK/STAT CAR-T cells by suppressing CD38 expression and inhibition of tyrosine kinase | Yasunori Amaishi, MS; Izumi Maki; Maiko Sugizaki; Kenichiro Mihara, M.D., Ph.D.; Sachiko Okamoto, PhD; Junichi Mineno, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;T cell;Targeted therapy;Tumor antigens | |
104 | Poster Presentation | Development and characterization of human chimeric antigen receptor Monocytes (CAR-Mono), a novel cell therapy platform | Daniel Blumenthal, PhD; Linara Gabitova, PhD; Brett Menchel; Patricia Reyes-Uribe; Andrew Best, BS, MS; Michael Lynch; Sotheavy Chhum; Maggie Schmierer; Sascha Abramson, PhD; Michael Klichinsky, PharmD, PhD | Cellular Therapies | Adoptive immunotherapy;Cytokine;Monocyte/Macrophage;Myeloid cells;Solid tumors | |
105 | Poster Presentation | 4-1BB and optimized CD28 co-stimulation enhances function of human mono- and bi-specific third-generation CAR T cells | Emiliano Roselli, Ph.D.; Justin C. Boucher; Gongbo Li; Hiroshi Kotani; Kristen Spitler; Kayla M. Reid, M.S.; Yannick Bulliard; Nhan Tu; Sae Bom Lee; Bin Yu; Frederick L. Locke, M.D.; Marco L. Davila, M.D., Ph.D. | Cellular Therapies | Adoptive immunotherapy;Bispecifics;CAR T cells | |
106 | Poster Presentation | Treatment with CC-99282 enhances antitumor function of the anti-CD19 CAR T cell therapy lisocabtagene maraleucel (liso-cel) | Archana Brahmandam, MS; Jim J. Qin, BS; Susan Kim; Yue Jiang; Brook Barajas; Soraya Carrancio; Leanne Peiser | Cellular Therapies | CAR T cells;Cytokine;Gene expression;Leukemia/Lymphoma;T cell;Targeted therapy | |
107 | Poster Presentation | Armoring NKG2D CAR T cells with IL-18 improves in vivo anti-tumor activity | Eytan Breman, MSc; Ann-Sophie Walravens; Isabelle Gennart; Amelie Velghe; Thuy Nguyen; Benjamin Violle; Fanny Huberty; Nancy Ramelot; Laure Twyffels; Emilie Gauthy; Hannes Iserentant; David E. Gilham, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell | |
108 | Poster Presentation | Fast and accurate prediction of optimal CAR T-cell function using z-Movi® Cell Avidity Analyzer | Will Singleterry, Phd; Andrea Candelli, PhD; Rogier M. Reijmers, PhD; Jens Eberlein, PhD | Cellular Therapies | CAR T cells;T cell;Tumor antigens;Tumor evasion | |
110 | Poster Presentation | IL-2 variant improves CAR-T functionality and efficacy against solid tumors | Qi Dong, Msc; Wenjie Yin, Ph.D.; Pengfei Jiang, Ph.D.; Manli Yin; Tao Wang; Ping Wang; Xinxin Wang, Ph.D.; William Wei Cao, Ph.D.; Lianjun Shen, Ph.D. | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
111 | Poster Presentation | Armored CAR T Cells Secreting 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor for Enhanced Solid Tumor Efficacy | Zachary S. Dunn, MS; Yun Qu, Doctorate; Melanie MacMullan; Xianhui Chen, Doctorate; Gunce Cinay; Pin Wang, Doctorate | Cellular Therapies | Adoptive immunotherapy;Antibody;Bispecifics;CAR T cells;Checkpoint blockade;Costimulation;Solid tumors;T cell;Tumor microenvironment | |
112 | Poster Presentation | Tumor-specific Reactivity and Effector Function of Chimeric Antigen Receptor Engineered Macrophages Targeting MUC1 | Seth H. Eisenberg; Amy A. Powers, MS; Jason C. Lohmueller, PhD; James D. Luketich, MD; Rajeev Dhupar, MD; Adam C. Soloff, PhD | Cellular Therapies | Adoptive immunotherapy;Antigen presenting cells;Monocyte/Macrophage;Tumor antigens | |
113 | Poster Presentation | CISH gene-knockout anti-CD70-CAR NK cells demonstrate potent anti-tumor activity against solid tumor cell lines and provide partial resistance to tumor microenvironment inhibition | Chao Guo, PhD; Yanying Fan; Alexander Aronov; Luxuan Buren, Ph.D.; Ming-Hong Xie, MD; Ivan H. Chan, PhD; Sasha Lazetic; James B. Trager, PhD | Cellular Therapies | NK/NKT cell;Tumor microenvironment | |
115 | Poster Presentation | An NFAT Promoter Based Fluorescent Jurkat Cell Platform for High-Throughput Screening of Chimeric Antigen Receptor (CAR) Constructs | Brikena Gjeci, MS; Sadik H. Kassim, PhD; Julian Scherer | Cellular Therapies | CAR T cells | |
116 | Poster Presentation | Development of Logic Gated CAR-NK cells for the treatment of solid tumors | Alba Gonzalez Junca, PhD; Nicholas Frankel, PhD; Marcus Gainer; Alyssa Mullenix; Miguel Palermo; Derrick Lee; Frances D. Liu, PhD; Russell M. Gordley, PhD; Chen-Ting Lee, PhD; Assen Roguev, PhD; Niran Almudhfar; Mengxi Tian; Gary Lee, PhD | Cellular Therapies | Immune toxicity;NK/NKT cell;Solid tumors;Tumor antigens | |
117 | Oral Presentation | FT536 Path to IND: Ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapy. | John Goulding, PhD; Bryan Hancock, PhD; Robert Blum, MS; Moyar Ge, PhD; Svetlana Gaidarova, MS; Paul Rogers, PhD; Sajid Mahmood, PhD; Rina Mbofung, PhD; Wen-I Yeh, PhD; Bi-Huei Yang, PhD; Chia-Wei Chang, PhD; Brian Groff, BS; Soheila Shirinbak, PhD; Joy Grant; Martin Hosking, PhD; Mochtar Pribadi; Yijia Pan; Hui-Yi Chu; Shohreh Sikaroodi, PhD; Lauren Fong, PhD; Nicholas Brookhouser, PhD; Fernanda Rodrigues Cugola, PhD; Ramzey Abujarour, PhD; Janel Huffman, MS; Pei-Fang Tsai, PhD; Antonio Fernandez-Perez, PhD; Karina Palomares, PhD; Natalie Marquez-Solorzano, MS; Riya Kanherkar, PhD; Andrew Burns, PhD; Aidan Keefe, MS; Samvel Nazaretyan, BS; Christine Chen, PhD; Raedun Clarke, PhD; Thomas Dailey, BS; Miguel Meza, BS; Jason O'Rouke, PhD; Jerome Bressi, PhD; Tom Lee; Ryan Bjordahl, PhD; Lucas Ferrari de Andrade, PhD; Kai W. Wucherpfennig, MD, PhD; Bahram Valamehr, PhD | Cellular Therapies | Adoptive immunotherapy;Chemotherapy;Clinical study;Leukemia/Lymphoma;NK/NKT cell;Radiotherapy;Solid tumors;Targeted therapy;Tumor antigens;Tumor evasion | |
118 | Poster Presentation | Development of Claudin 18.2 TAC T cells for the treatment of gastric cancer | christopher CW. Helsen, PhD; Tania Benatar, PhD; Philbert IP, PhD; Stacey Xu, PhD; Laura Shaver; Thanyashanthi Nitya-Nootan, MSc; Andreas G. Bader; Prabha Lal, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell | |
119 | Poster Presentation | ADI-002: an IL-15 armored allogeneic “off-the-shelf” Vδ1 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3) | Amani Makkouk, PhD; Xue (Cher) Yang; Taylor Barca; Anthony Lucas; Mustafa Turkoz; Jonathan Wong; Kevin P. Nishimoto; Mary M. Brody; Maryam Tabrizizad; Smitha Gundurao; Lu Bai; Arun Bhat; Zili An; Stewart Abbot; Daulet Satpayev; Marissa Herrman | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell;Tumor antigens | |
120 | Poster Presentation | Chemokine receptor engineering enhances trafficking and homing of primary and iPSC-derived CAR-T cells to solid tumors | Martin Hosking, PhD; Soheila Shirinbak, PhD; Joy Grant; Yijia Pan; Angela Gentile; Amit Mehta; Bjoern Gaertner, PhD; Bishwas Shrestha, PhD; Mochtar Pribadi; Jason ORourke, PhD; Alec Witty; Tom Lee; Bob Valamehr, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Chemokine;Chemotherapy;Radiotherapy;Solid tumors;T cell;Tumor microenvironment | |
121 | Poster Presentation | ICAM-1-specific affinity tuned CAR T cells expressing SSTR2 for real-time imaging | Jingmei Hsu, MD, PhD; Eric von Hofe, PhD; Michael Hsu, MD, PhD; Koen Van Besien, MD; Thomas Fahey, MD; Jana Ivanidze, MD, PhD; Janusz Puc, PhD; Karrie Du, PharmD; Moonsoo M. Jin, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell | |
122 | Poster Presentation | A powerful, precise targeting system controlled by tumor deletions transforms CEA and MSLN CAR-T cells into tumor-selective agents | Agnes Hamburger; Han Xu, PhD; Yuta Ando; Grace Asuelime; Kristian Bolanos-Ibarra; Mark Daris, PhD; Kiran Deshmukh; Breanna DiAndreth; Fernando Fisher; Grant Gabrelow; Maria Imun; David Ju; Wen-Hua Lee; Chuck Li; Edwin Liu; Aaron D. Martin, M.A.; Michele Mcelvain; Jee-Young Mock; Daniel Nampe; Martin Naradikian; Mark Sandberg, PhD; Sanam Shafaattalab; Shruti Sharma; Talar Tokatlian; Dora Toledo-Warshaviak; Xueyin Wang, PhD; Lu-Min Wong; Alexander Kamb, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Tumor antigens | |
123 | Poster Presentation | P-MUC1C-ALLO1: A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy with Broad Potential in Solid Tumor | Yan Zhang, Ph.D.; Anna K. Kozlowska, Ph.D.; Jacqueline Fritz; Yingying Zhao; Claudia Palomino La Torre; Stacey Cranert, Ph.D.; Steven Wang; Rebecca Codde; Elvira Argus, Ph.D.; Samad Ibitokou, Ph.D.; Vanitra Richardson; Sumiti Jain, Ph.D.; Maximilian Richter, Ph.D.; Deepak Patil, Ph.D.; Yening Tan; Min Tong; Lu Yao, Ph.D.; Majid Ghoddusi, Ph.D.; Eric M. Ostertag, Ph.D. M.D.; Julia Coronella, Ph.D.; Devon J. Shedlock, Ph.D. | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell | |
124 | Poster Presentation | Functionalizing CAR T cells for selective proliferation and dual-targeting using the meditope technology | Cheng-Fu Kuo, MS; Yi-Chiu Kuo; Miso Park; Zhen Tong; Brenda Aguilar; Agata Xella; Vanessa Salvary; Stephen J. Forman; John C. Williams, PhD; Christine Brown, PhD | Cellular Therapies | Antibody;CAR T cells;T cell | |
125 | Poster Presentation | Co-opting IL-8 to enhance efficacy of B7H3 CAR T cells against pediatric sarcoma | Jessica Lake, MD MPH; Kevin Winkler, BA; Alexander Harrant, BS; Ashley Yingst, MS; Kristin Schaller, PhD; Eric Hoffmeyer, BS; Madeline Larson, BS; Dejene Tufa, PhD DVM; Laura Cobb, MD; Dallas Jones, PhD; Michael Verneris, MD | Cellular Therapies | CAR T cells;Chemokine;Pediatric tumors;Radiotherapy;Solid tumors;T cell | |
126 | Poster Presentation | Regional administration of IL-12 endowed CAR T cells effectively targets systemic disease | Hee Jun Lee, BA; Cody Cullen; John P. Murad; Jason Yang; Wen-Chung Chang; Stephen J. Forman; Saul Priceman, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell | |
127 | Poster Presentation | CAR T cells targeting the integrin alpha v beta 3 exhibit robust anti-tumor responses against diffuse intrinsic pontine glioma and glioblastoma | Dustin A. Cobb, PhD; Jacopo de Rossi; Lixia Liu; Erin An; Daniel W. Lee, III, MD | Cellular Therapies | CAR T cells;Pediatric tumors;Solid tumors;T cell;Targeted therapy | |
128 | Poster Presentation | KIR haplotype can inform donor selection production of allogeneic memory-like CAR NK cells for clinical application | Hadia Lemar, BS; Anmol Vohra, MS; Ming-Hong Xie, MD; Ivan H. Chan, PhD; Sasha Lazetic; James B. Trager, PhD | Cellular Therapies | Cytokine;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy | |
129 | Poster Presentation | Development of AB-201, a novel allogeneic anti-HER2-specific CAR-NK cell therapy for the treatment of HER2+ tumors | Hoyong Lim, PhD; Amanda Medcalf; Lisa Guerrettaz, PhD; Eun Ji Choi; Hansol Kim; Bitna Yang; Eun Ji Kim; Eun-Sol Lee; Jeong Min Kim; Yusun Kim; Bokyung Min; Sang-Min Paik; Hyeong Jin Nam; Seungryel Han; Srinivas Somanchi, PhD; Eugene Helsel; Jason Litten, MD; Peter Flynn, PhD; Heather Raymon, PhD; Yu-Kyeong Hwang, PhD | Cellular Therapies | NK/NKT cell;Solid tumors | |
130 | Oral Presentation | Engineered natural killer cells reactively block TIGIT and CD73 in the GBM microenvironment | Kyle B. Lupo, BS; Sandro Matosevic, PHD | Cellular Therapies | Adoptive immunotherapy;Immune suppression;NK/NKT cell;Solid tumors;Targeted therapy;Tumor microenvironment | |
131 | Poster Presentation | Genetic disruption of negative immune regulators to enhance CAR-T efficacy against solid tumors | David Mai, BS; Omar S. Johnson; Carl H. June, MD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell | |
132 | Oral Presentation | HLA-independent T cell receptors effectively target low abundance antigens | Jorge Mansilla-Soto, PhD; Justin Eyquem; Sascha Haubner; Mohamad Hamieh; Judith Feucht; Noémie Paillon; Andres E. Zucchetti; Zhuoning Li; Maria Sjöstrand; Pieter L. Lindenbergh; Michelle Saetersmoen; Mathieu Maurin; Archana Iyer; Anton Dobrin; Andreina Garcia Angus; Matthew M. Miele; Zeguo Zhao; Theodoros Giavridis; Sjoukje JC. van der Stegen; Fella Tamzalit; Morgan Huse; Ronald C. Hendrickson; Claire Hivroz; Michel Sadelain | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;T cell | |
133 | Poster Presentation | CRISPR/Cas9 gene-edited allogeneic CAR-T cells targeting CD33 show high preclinical efficacy against AML without long-term hematopoietic toxicity | Jonathan Terrett, PhD; Brigid Mcewan, MA; Daniel Hostetter; Luis Gamboa; Meghna Kuppuraju; Mohammed Ghonime; Robert Chain; Zinkal Padalia; Demetrios Kalaitzidis | Cellular Therapies | CAR T cells | |
135 | Poster Presentation | Identification and Characterization of an allogeneic iNKT-CAR targeting BCMA | Xavier Michelet, PhD; Eleni Chantzoura, PhD; Efrat Altman-Sharoni; Martyna Popis; Reed Masakyan; Paul Ibbett; Deborah Wright; Moira Pinzan Rossi; Marc A. Van Dijk, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy | |
136 | Poster Presentation | ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors | Xianhui Chen, PhD; Jiangyue Liu; Shuai Yang; Amogh Oke; Sarah Davies; Bryan Ruiz-Juarez; Yannick Bulliard; Cokey Nguyen | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
137 | Poster Presentation | Development of anti-Mucin1 CAR-T against solid tumors | Jihyun Lee, Ph.D.; Areum Park, Ph. D.; Jungwon Choi; Dae Gwan Yi, Ph. D.; Hee Jung Yang, Ph. D.; Hae-youn Lee, Ph.D.; Eurim Song; Sung Woong Jang, Ph.D.; Hyoju Yi, Ph.D.; Heedong Park; Eun-ji Jeun, Ph.D.; Minjeong Park; Peter S. Hong, Ph.D. | Cellular Therapies | CAR T cells;T cell | |
138 | Poster Presentation | Synthetic re-direction of TGFβ receptors as a novel strategy to enhance the anti-tumor activity of CAR-T cells in solid tumors | Eigen Peralta; Emily Carron, PhD; Hui-Yi Chu; Lorraine Loter; Natalie Navarrete; Arvin Tam; Amit Mehta; Dan Lu; Philip Chu; Kenyon Lyon; Yijia Pan; Mochtar Pribadi; Alec Witty; Tom Lee; Bob Valamehr, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment | |
139 | Poster Presentation | Chimeric antigen receptor macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD1 blockade in immunocompetent mouse models of HER2+ solid tumors | Stefano Pierini, PhD; Michael Klichinsky, PharmD, PhD; Rashid Gabbasov, PhD; Alison Worth; Ilyssa Ramos; Daniel Blumenthal, PhD; Linara Gabitova, PhD; Sascha Abramson, PhD; Thomas Condamine, PhD; Michael Ball; Yumi Ohtani, PhD | Cellular Therapies | Adoptive immunotherapy;Checkpoint blockade;Monocyte/Macrophage;Solid tumors;Tumor microenvironment | |
140 | Poster Presentation | Allogeneic CAR T cells with deoxycytidine kinase knockdown demonstrate resistance to fludarabine | Michelle B. Pires, MS; Aaron J. Martin, PhD | Cellular Therapies | CAR T cells;T cell | |
142 | Poster Presentation | Enhanced antitumoral activity of HER2-CAR-Ts in comparison to Trastuzumab in a live cell imaging supported 3D assay | Katharina Schaich, MSc; Gemma Moiset; Sophie C. Vermond, MSc; Monique Hazenoot; Kanstantsin Lashuk; Eva Oswald, PhD; Sanne Holt; Julia Schuler, DVM PhD | Cellular Therapies | Antibody;CAR T cells;Solid tumors;T cell;Tumor antigens | |
143 | Poster Presentation | Mesothelin (MSLN) targeting allogeneic CAR T cells engineered to overcome tumor immunosuppressive microenvironment | Cecile Schiffer-Mannioui; Sophie Leduc; Isabelle Chion-Sotinel; Diane le Clerre; Valérie Guyot; Marco Rotondi; Roman Galetto, PhD; Agnès Gouble | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
144 | Poster Presentation | SIRP⍺ deficient CAR-Macrophages exhibit enhanced anti-tumor function and bypass the CD47 immune checkpoint | Chris Sloas, PhD; Rashid Gabbasov, PhD; Nicholas R. Anderson, PhD; Sascha Abramson, PhD; Michael Klichinsky, PharmD, PhD; Yumi Ohtani, PhD | Cellular Therapies | Adoptive immunotherapy;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment | |
145 | Poster Presentation | Comparison of CAR-T cell manufacturing platforms reveals distinct phenotypic and transcriptional profiles | Hannah W. Song, PhD; Lipei Shao, PhD; Michaela Prochazkova; Adam Cheuk, PhD; Ping Jin, PhD; David F. Stroncek, MD; Javed Khan, MD; Steven L. Highfill, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Clinical study;Gene expression;Solid tumors;T cell | |
146 | Poster Presentation | Evolving Mutliplexed shRNA to generate tailored CAR T cell therapy | Mikhail Steklov; Benjamin Lecalve; Jerome Marijse; Fanny Huberty; Nancy Ramelot; Celine Jacques-Hespel; Hannes Iserentant; Eytan Breman, MSc; David E. Gilham, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;T cell | |
147 | Poster Presentation | Memory phenotype in allogeneic anti-BCMA CAR-T cell therapy (P-BCMA-ALLO1) correlates with in vivo tumor control | Hubert Tseng, PhD; Yan Zhang, Ph.D.; Stacey Cranert, Ph.D.; Maximilian Richter, Ph.D.; Karl Marquez; Jing Qiu; Benjamin Cho; Yening Tan; Min Tong, MS; Christine Domingo, BS; Leslie A. Weiss, M.S.; Elvira Argus, Ph.D.; Jessica Sparks; Eric M. Ostertag, Ph.D. M.D.; Julia Coronella, Ph.D.; Devon J. Shedlock, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;T cell | |
148 | Poster Presentation | Primary or iPSC-derived cell-based cytotoxicity assays to assess potential safety risks of engineered T cell therapies in vitro | Sophie C. Vermond, MSc; Monique Hazenoot; Rene McLaughlin; Sabrina de Munnik; Marco Guadagnoli; Gemma Moiset; Sanne Holt; Marijn Vlaming | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
149 | Poster Presentation | In vitro efficacy studies to support engineered T cell therapies | Sabrina de Munnik; Monique Hazenoot; Sophie C. Vermond, MSc; Rene McLaughlin; Marco Guadagnoli; Gemma Moiset; Sann Holt; Marijn Vlaming | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;T cell;Targeted therapy;Tumor antigens | |
150 | Poster Presentation | Targeted delivery of a PD-L1-blocking scFv by CAR-NK cells shows potential as a new approach to immunotherapy for glioblastoma | Jiao Wang, PhD; Sandro Matosevic, PHD | Cellular Therapies | Adoptive immunotherapy;Checkpoint blockade;Immune suppression;NK/NKT cell;Solid tumors;Targeted therapy;Tumor microenvironment | |
151 | Poster Presentation | Potentiating the Large-Scale Expansion and Engineering of Peripheral Blood-Derived CAR NK Cells for Off-the-Shelf Application | Michael I. Whang, PhD; Ming-Hong Xie, MD; Kate Jamboretz, MS; Hadia Lemar, BS; Chao Guo, PhD; Nafees Rahman, PhD; Ivan Chan, PhD; Erik M. Whiteley, PhD; Ralph Brandenberger, PhD; Sasha Lazetic; James B. Trager, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;NK/NKT cell;Targeted therapy | |
152 | Oral Presentation | Common trajectories of highly effective anti-CD19 chimeric antigen receptor-modified T cells identified by endogenous T cell receptor lineages | Taylor L. Wilson, BS; Hyunjin Kim, PhD; Jeremy C. Crawford, PhD; Ching-Heng Chou, PhD; Deanna Langfitt, PhD; E. Kaitlynn Allen, PhD; Timothy Lockey, PhD; Michael Meagher, PhD; Aimee C. Talleur, MD; Stephen Gottschalk, MD; Paul G. Thomas, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Gene expression;T cell;T cell lineages | |
153 | Poster Presentation | Nanoscale, antigen-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment | Zhifen Yang, Dr.; Francesco M. Marincola, MD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
154 | Poster Presentation | Context-dependent reversible modulation of cJUN expression by CAR T cells for cancer treatment | Zhifen Yang, Dr.; Francesco M. Marincola, MD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
155 | Poster Presentation | CD5 knockout enhances the potency of multiplex base-edited allogeneic anti-CD5 CAR T-cell therapy for the treatment of T-cell malignancies | Yinmeng (Amy) Yang, PhD; Ryan Murray; Adam J. Camblin, PhD; Faith Musenge; Lindsey Coholan; MarkVic Naniong; David Sweezy; Scott Haskett; Lauren Young; Yingying Zhang, PhD; Amanda Costa; Hui Wu; Alden Ladd; Luis Barrera, PhD; Lisa Schlehuber, PhD; Sarah Smith; Yeh-Chuin Poh, PhD; Giuseppe Ciaramella, PhD; Jason Gehrke, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;T cell | |
156 | Poster Presentation | RBC-Derived, Activating Antigen Carriers (SQZ AACs) Prime Potent T Cell Responses and Drive Tumor Regression In Vivo | Katarina Blagovic, PhD; Carolyne Smith, PhD; Lindsay Moore; Emrah Ilker Ozay, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Scott M. Loughhead, PhD | Cellular Therapies | Adoptive immunotherapy;Chemotherapy;Immune adjuvant;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine | |
157 | Poster Presentation | Lymph node targeted boosting with cognate Amphiphile-peptide vaccines enhances TCR-T Cell therapy to eradicate solid tumors | Dylan J. Drakes, PhD; Abdulraouf M. Abbas, M.Sc.; Jacqueline Shields; Peter C. DeMuth, PhD | Cellular Therapies | Adoptive immunotherapy;Immune adjuvant;Solid tumors;T cell;Targeted therapy;Vaccine | |
158 | Poster Presentation | Chemotherapy Resistant Gamma Delta T-cell Immunotherapy can leverage synergistic ligand expression through combinational chemotherapy and PARP-inhibitor use to enhance tumor cell recognition & killing | Kate M. Rochlin, PhD; Amber Jones; Lawrence S. Lamb, Jr., PhD; Anita Hjelmeland, PhD | Cellular Therapies | Checkpoint blockade;Chemotherapy;Gene expression;Solid tumors;T cell;Tumor antigens | |
159 | Poster Presentation | Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers | Irene Raitman, PhD; John Fitzgerald, BS; Valentina Rousseva, MS; Salvatore Rotondo, MS; Xuan Guo, PhD; Hemlata Rana, MS; Andrea DiFiglia, BS; Tanel Mahlakoiv, PhD; Shuyang He, PhD; Lin Kang, PhD; Robert Hariri, MD PhD; Xiaokui Zhang, PhD | Cellular Therapies | Antibody;NK/NKT cell;Solid tumors;Targeted therapy | |
160 | Poster Presentation | Evaluation and development of dual and triple antigen targeting CAR-T Engager proteins for Her2-positive CNS metastases and solid tumors | Paul D. Rennert, PhD; Lan Wu, PhD; Lihe Su, PhD; Roy R. Lobb, PhD; Christine Ambrose, PhD | Cellular Therapies | Adoptive immunotherapy;Bispecifics;CAR T cells;Tumor antigens | |
161 | Poster Presentation | Anti-myeloid poly-pharmacy combined with FGFR4-targeted chimeric antigen receptors (CARs) effectively treats orthotopic rhabdomyosarcoma, modeling CAR effectiveness for solid tumors | Peter M. Sullivan, PhD; Rajesh Kumar, PhD; Wei Li, PhD; Lingyang Wang, PhD; Yue Zhang, MS; Adam Cheuk, PhD; Javed Khan, MD; Dimiter S. Dimitrov, PhD; Rimas J. Orentas, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Myeloid cells;Pediatric tumors;Solid tumors;Targeted therapy;Tumor microenvironment;Tumor stroma | |
162 | Poster Presentation | Nicotinamide rejuvenates ex-vivo expanded natural killer cells and enhances their tumor killing capacity | Aviad AP. Pato, Dr, PhD; Astar Hailu; Nurit Brickman; Dima Yackoubov; Frank S. Cichocki, PhD; Amnon Peled, PhD; Yona Geffen, PhD; Avishay Edri, PhD; Ronit Simantov, MD; Tracey Lodie, PhD; Julia Rifman, PhD; Orit Berhani-Zipori, PhD; Aviad Pato | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;Solid tumors | |
163 | Poster Presentation | Improved anti-tumor activity of next-generation TCR-engineered T cells through CD8 co-expression | Gagan Bajwa; Justin T. Gunesch; Inbar Azoulay-Alfaguter; Melinda Mata; Ali Mohamed; Mamta Kalra; Steffen Walter | Cellular Therapies | Adoptive immunotherapy;Antigen presenting cells;Costimulation;Cytokine;T cell;Targeted therapy;Tumor microenvironment | |
164 | Poster Presentation | Potent Tumor Organoid Infiltration and Killing by PBMC-Derived Effector Cells | Frank Borriello, MD, PhD; Joshua Keegan; James A. Lederer, PhD | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;T cell | |
165 | Poster Presentation | Generating Enhanced Tumor Infiltrating Lymphocytes Through Microfluidic Cell Squeezing | Devin Bridgen, PhD; Arindam Bhattacharjee; Colin J. Thalhofer, PhD; Ryan D. Montler, MBA; Andrew D. Weinberg, PhD; Armon Sharei, PhD; Jonathan Gilbert, PhD | Cellular Therapies | Cytokine;RNA;T cell;Tumor infiltrating lymphocytes (TILs) | |
166 | Poster Presentation | Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo | Rachel A. Burga, PhD; Mithun Khattar, PhD; Scott Lajoie; Kyle Pedro, PhD; Colleen Foley; Alonso Villasmil Ocando; Jack Tremblay; Benjamin Primack; Meghan Langley, BS; Dan Thornton; Stanley Tam; Emily Brideau; Theresa Ross; Gwen Wilmes, PhD; Sunandan Saha, PhD; Gabriel Helmlinger, PhD; Jeremy Tchaicha, PhD; Dhruv Sethi, PhD; Michelle L. Ols, PhD; Gary Vanasse, MD; Shyam Subramanian, PhD; Jan ter Meulen, MD, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
167 | Poster Presentation | High-efficiency capture of anti-tumor neoantigen-reactive T cell receptors from tumor digest | Praveen D. Chatani, MD; Frank J. Lowery, PhD; Neilesh B. Parikh, M.D.; Rami Yossef, PhD; Victoria Hill, PhD; Zhiya Yu, PhD; Todd D. Prickett, PhD; Jared Gartner; Biman C. Paria, M.S.; Satyajit Ray; Maria Florentin; Paul F. Robbins, PhD; Sri Krishna, PhD; Steven A. Rosenberg, MD, PhD | Cellular Therapies | Adoptive immunotherapy;Biomarkers;Clinical study;Neoantigens;T cell;T cell lineages;Tumor antigens | |
168 | Poster Presentation | Expanding and characterizing tumor infiltrating lymphocytes from myxofibrosarcoma and undifferentiated pleomorphic sarcoma | Jacky HK. Chen, HBSc; Jay S. Wunder, MD., MSc; Kim Tsoi, MD., PhD; Nalan Gokgoz, PhD; Irene L. Andrulis, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Costimulation;Cytokine;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
169 | Poster Presentation | Off-the-shelf, engineered iPSC-derived NK cells mediate potent cytotoxic activity against primary glioblastoma cells and promote durable long-term survival in vivo | Frank S. Cichocki, PhD; Jianfang S. Ning; Zachary B. Davis, PhD; Hongbo S. Wang; Katie S. Tuininga; Ryan Bjordahl, PhD; Paul Rogers, PhD; Moyar Ge, PhD; Tom Lee; Bob Valamehr, PhD; Clark C. Chen, MD; Jeffrey S. Miller, MD | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell | |
170 | Poster Presentation | Novel gene editing approach to enhance CD38-directed antitumor activity of primary human natural killer cells | Joseph A. Clara, MD; Emily Levy; Robert Reger; Mala Chakraborty; David Allan; Richard W. Childs, M.D. | Cellular Therapies | Adoptive immunotherapy;Antibody;NK/NKT cell;Targeted therapy | |
171 | Poster Presentation | Targeting the Immunomodulatory Roles of T-cell immunoglobulin– and mucin domain–containing (TIM)–3 on Natural Killer Cells in Glioblastoma | Tram N. Dao; Sandro Matosevic, PHD | Cellular Therapies | Adoptive immunotherapy;Metabolism;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
172 | Poster Presentation | Overcoming immunosuppressive TGF-β signaling in human ovarian cancer-derived tumor infiltrating lymphocytes via non-viral CRISPR engineering | Samantha M. Fix, PhD; Marie-Andrée Forget; Donastas Sakellariou-Thompson, BS; Yunfei Wang; Ana Lucía Dominguez; Rafet Basar; Christopher Reyes; Sanjay Kumar; Larissa A. Meyer; Patrick Hwu; Chantale Bernatchez, PhD; Amir Jazaeri, MD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
173 | Poster Presentation | Expression of a membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence of MSLN-targeted TRuC-T cells | Michelle Fleury, PhD; Derrick P. McCarthy, PhD; Holly Horton, PhD; Courtney Anderson, PhD; Amy Watt; Adam Zieba, MS; Lindsay Webb, PhD; Jian Ding, PhD; Robert Tighe; Robert Hofmeister, PhD; Dario Gutierrez, PhD | Cellular Therapies | Cytokine;Solid tumors;T cell | |
174 | Poster Presentation | Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes | Meredith Frank, MSc; Parin Shah; Marie Andree Forget, PhD; Lorenzo Federico, PhD; Peixin Jiang; Roohussaba Khairullah; Ignacio Wistuba, MD; Chi-Wan Chow; Yan Long; Junya Fujimoto; Shiaw-Yih Lin, Ph.D.; Anirban Maitra, MBBS; Marcelo V. Negrao, MD; Kyle Mitchell, MD; Annika Weissferdt, MD; Ara A. Vaporciyan, MD; Tina Cascone, MD, PhD; Jack Roth; Jianjun Zhang, MD, PhD; Boris Sepesi, MD; Don L. Gibbons, MD, PhD; John V. Heymach, MD, PhD; Cara Haymaker, PhD; Daniel J. McGrail, PhD; Chantale Bernatchez, PhD; Alexandre Reuben, PhD | Cellular Therapies | Adoptive immunotherapy;Clinical study;Neoantigens;Solid tumors;T cell;T cell lineages;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
175 | Poster Presentation | High-dose TIL product with improved phenotype and functionality | Christina Friese, PhD; Christina Heeke, PhD; Nikolaj Kirketerp-Møller, MS; Sandra Færch; Maria Juul Nielsen; Amalie Hey, PhD; Ulrik Cordes | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
176 | Poster Presentation | Successful generation of tumor-infiltrating lymphocyte (TIL) product from renal cell carcinoma (RCC) tumors for adoptive cell therapy | Brian Halbert, MD MPH; David Einstein, MD; David F. McDermott, MD; Emanuelle I. Andrianopoulos; Mamta Gupta, MD; Virginia Seery, MSN, RN, ANP-BC; Kenneth Onimus; Courtney Herman; Adrian Wells; Shwetha Lakshmipathi; Arvind Natarajan; Anand Veerapathran; Rupal Bhatt, MD, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
177 | Poster Presentation | Treatment outcomes with unselected autologous tumor infiltrating lymphocytes in patients with checkpoint inhibition–refractory advanced cutaneous melanoma | Robert E. Hawkins, MD, PhD; Yizhou Jiang; Paul C. Lorigan; Fiona C. Thistlethwaite; Manon Pillai; Martine Thomas; Natalia Kirillova; John S. Bridgeman; Gray Kueberuwa; Ryan D. Guest; Zachary J. Roberts | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
178 | Poster Presentation | Expansion of Tumor-Infiltrating Lymphocytes and Marrow-Infiltrating Lymphocytes from Pediatric Malignant Solid Tumors | Jonathan Metts, MD; Jonathan A. Hensel, PhD; Alejandro Alfaro; Brook Olmo; Shari A. Pilon-Thomas, PhD; John E. Mullinax, MD; Ivanna Leon | Cellular Therapies | Adoptive immunotherapy;Pediatric tumors;Solid tumors;T cell | |
179 | Poster Presentation | CD8+CD69+ Expanded Tumor Infiltrating Lymphocytes from Soft Tissue Sarcoma Have Increased Tumor-Specific Functional Capacity | Jonathan A. Hensel, PhD; Alejandro Alfaro; Mary Rau; Patricio Perez-Villarroel; Zachary Sannasardo; Shari A. Pilon-Thomas, PhD; John E. Mullinax, MD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
180 | Poster Presentation | T Cell Phenotype Drives Restructuring of Tumor Microenvironment to Balance T Cell Longevity and Tumor Control: Insights from Multiplexed Imaging and Multi-scale Agent Based Modeling | John W. Hickey, PhD; Garry P. Nolan, PhD; Markus Covert; Eran Agmon; Nina B. Horowitz, MS; John B. Sunwoo, MD | Cellular Therapies | Adoptive immunotherapy;Bioinformatics;CAR T cells;Immune contexture;Immune monitoring;Solid tumors;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
181 | Poster Presentation | Intraepithelial group 1 innate lymphoid cells generated in vitro exhibit enhanced cytotoxicity and infiltration into solid tumoroids | Nina B. Horowitz, MS; John W. Hickey, PhD; John B. Sunwoo, MD | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
183 | Poster Presentation | Therapeutic T cells exhibit distinct vulnerability to glucose deprivation in tumors which can be overcome with an engineered glucose transporter | Jessica A. Jana, BSE; Yiyang Wang, N/A; Ashley Menk, MS; Andrew Frisch, BS; Greg M. Delgoffe, PhD | Cellular Therapies | Metabolism;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
184 | Poster Presentation | Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers | Peter Kim, PhD; Steven A. Rosenberg, MD, PhD; Nolan Vale | Cellular Therapies | Adoptive immunotherapy;Neoantigens;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs) | |
185 | Poster Presentation | Ex vivo efficacy of adoptive T cell therapy using autologous CD8+ T cells isolated by PD-1 positivity from peripheral blood mononuclear cells in solid tumors | Sungkyu Lee, Ph.D; yong wha Moon | Cellular Therapies | Adoptive immunotherapy;Coinhibition;Neoantigens;Solid tumors;T cell;T cell lineages;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
186 | Poster Presentation | Development of KSQ-001, an engineered TIL (eTIL) therapy for solid tumors through CRISPR/Cas9-mediated editing of SOCS1 | Karrie K. Wong, PhD; Sharon Lin, PhD; Christopher Wrocklage; Katri Sofjan; Leila Williams; Mallory Brady; Nicholas Colletti, PhD; Noah Tubo; Hugh Gannon; Robert A. LaMothe; Tianlei Xu, PhD; Tracy VandenBerg; Sol Shenker, PhD; Caroline Dugopolski; Frank Stegmeier, PhD; Louise Cadzow; Michael Schlabach, PhD; Micah J. Benson, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
187 | Poster Presentation | Multi-omic single-cell profiling demonstrates that competition for fatty acids and fatty acid oxidation enables tumor-infiltrating lymphocyte function and survival | Melisa Angela M. Paniagua, PhD; Melisa A. Martinez Paniagua, PhD; Cara Haymaker, PhD; Jay R Adolacion; Xingyue An, BS; Caitlin Creasy, MS; Mohsen Fathi; Ali Rezvan; Tamar Geiger; Michal Harel; Jonathan Robinson; Amit Amritkar; Scott Woodman; Patrick Hwu; Chantale Bernatchez, PhD; Navin Varadarajan, PhD | Cellular Therapies | Adoptive immunotherapy;Gene expression;Metabolism;Proteomics;RNA;Tumor infiltrating lymphocytes (TILs) | |
188 | Poster Presentation | Development of WU-NK-101, a feeder cell-free expanded allogeneic memory NK cell product with potent anti-tumor activity. | Ryan Sullivan, PhD; Mary Mathyer; Jennifer Govero; John Dean; Andrew Martens; You Zhou; Malik Darwech; Brunda Tumala; Alex Vessoni; Alexander Hamil; Tom Leedom; Corey Johnson; Melissa Berrien-Elliot; Mark Foster; Michelle Becker-Hapak; Ethan McClain; Carly Neal; Todd A. Fehniger, MD, PhD; Niraj Shrestha, PhD; Mike Dee; Hing C. Wong, PhD; Ayman Kabakibi; Matthew L. Cooper; Ken Chrobak | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;NK/NKT cell;T cell | |
189 | Poster Presentation | Targeting a novel shared tumor-specific antigen with T cell receptor transduced T cells for the treatment of ovarian cancer | Justyna Ogonek, PhD; Justyna Ogonek; Tiziana Franceschetti; Andreas Acs; Alexander Schmidt; Alexandra Kuhlenkamp; Krystel Vincent; Claude Perreault; Barbara Loesch; Adriana Turqueti Neves; Slavoljub Milosevic; Dolores J. Schendel; Daniel Sommermeyer | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor antigens | |
190 | Poster Presentation | Patient-derived tumor organoids reveal mechanisms of immune evasion which can guide decisions in adoptive cell therapy for common epithelial cancers | Anup Y. Parikh, MD; Maria Parkhurst, PhD; Paul F. Robbins, PhD; Steven A. Rosenberg, MD, PhD; James C. Yang, MD, PhD | Cellular Therapies | Adoptive immunotherapy;Gene expression;Neoantigens;RNA;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs) | |
191 | Poster Presentation | GAPDH knock-in of high affinity CD16 in iPSC derived NK cells drives high-level expression and increased anti-tumor function | Rithu Pattali; Kaitlyn M. Izzo; Edward J. Goncz; Steven Sexton; Kevin M. Wasko; John A. Zuris, Ph.D.; Michael Nehil, Ph.D.; Kate Zhang, Ph.D.; Mark Shearman, Ph.D.; Kai-Hsin Chang, Ph.D.; Alexander G. Allen, Ph.D. | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;Solid tumors | |
192 | Poster Presentation | POoled T Cell Receptor Screening (POTS) Provides Unbiased, High-Throughput Method for TCR Discovery | Jack L. Reid, BSc; Shihong Zhang, Ph.D; Ariunaa Munkhbat; Matyas Ecsedi, MD, PhD; Megan S. McAfee, PhD; Aude Chapuis, MD | Cellular Therapies | Adoptive immunotherapy;T cell;Tumor antigens | |
193 | Poster Presentation | The Achilles VELOSTM Process 2 boosts the dose of highly functional clonal neoantigen-reactive T cells for precision personalized cell therapies | Eleni Kotsiou, PhD; Joe Robinson; Amber Rogers; Daisy Melandri; Amy Baker; Anabel Ramirez Aragon; Sidra Nawaz; Michael Epstein; Shreenal Patel; Jennine Mootien; Andrew W. Craig, PhD; Satwinder Kaur-Lally; Hinal Patel; Andreas Schmitt; Farah Islam; Mariam Jamal-Hanjani; David Lawrence; Martin Foster; Samra Turajlic, MD PhD; Sergio A. Quezada, PhD; Katy Newton, BSc PhD | Cellular Therapies | Adoptive immunotherapy;Dendritic cell;Neoantigens;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
195 | Poster Presentation | Stimulation of tumor infiltrating B-cells improves ex-vivo TIL expansion for melanoma immunotherapy | Renata AM. Rossetti, PhD; Leticia Tordesillas; Matthew Beatty, PhD; Yian Ann Chen; Dongliang Du; Amod A. Sarnaik; Shari A. Pilon-Thomas, PhD; Daniel Abate-Daga, PhD | Cellular Therapies | Adoptive immunotherapy;B cell;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
196 | Poster Presentation | TLR9-activated B cells directly license adoptively transferred CD8+ T cells with potent tumor immunity | Aubrey S. Smith, BS; Hannah M. Knochelmann, BS; Megan M. Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Brandon Ware, PhD; Amalia M. Rivera Reyes, BS; Connor J. Dwyer, PhD; David M. Neskey, MD; Mark P. Rubinstein, PhD; Bei Liu, MD MPH; Jessica E. Thaxton, PhD, MS; Eric C. Bartee, PhD; Chrystal M. Paulos, PhD | Cellular Therapies | Adoptive immunotherapy;Antigen presenting cells;B cell;Costimulation;Solid tumors;T cell;TLR;Tumor infiltrating lymphocytes (TILs) | |
197 | Poster Presentation | Novel FcyR recombinant fusion facilitates antibody arming of engineered iPSC-derived NK cells to enhance targeting and killing of ovarian cancer cells | Kristin M. Snyder, DVM/PhD Student; Kate Dixon, PhD; Melissa Khaw; Zachary B. Davis, PhD; Paul Rogers, PhD; Martin Hosking, PhD; Ryan Bjordahl, PhD; Bahram Valamehr, PhD; Jianming Wu, DVM/PhD; Bruce Walcheck, PhD | Cellular Therapies | Antibody;NK/NKT cell;Solid tumors | |
198 | Poster Presentation | Costimulatory antigen receptor (CoStAR): a novel platform that enhances the activity of tumor infiltrating lymphocytes (TILs) | Sujita Sukumaran, PhD; Milena Kalaitsidou; Michelle Mojadidi; Clare Yarka; Yong (Stella) Ouyang; Eric Gschweng; Gray Kueberuwa; John S. Bridgeman, PhD; Bob Hawkins; Rubén Alvarez-Rodríguez | Cellular Therapies | Adoptive immunotherapy;Antibody;Costimulation;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
199 | Poster Presentation | Potent T cell costimulation mediated by a novel costimulatory antigen receptor (CoStAR) with dual CD28/CD40 signaling domains to improve adoptive cell therapies | Martina Sykorova; Leyuan Bao; Cynthia Chauvin-Fleurence; Milena Kalaitsidou; Michelle Le Brocq; Robert E. Hawkins, MD, PhD; Gray Kueberuwa; John S. Bridgeman, PhD; Rubén Alvarez-Rodríguez | Cellular Therapies | Adoptive immunotherapy;Antibody;Costimulation;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
200 | Poster Presentation | TGFβ-Armoring Boosts Potency and Persistence of Engineered TCR T Cells, Unlocking Superior Efficacy Against HPV-positive Solid Tumors | Gail D. Turner, PhD; Gabriela Diaz, BS; Andreia Costa, PhD; Yeonjoo Oh, MS; Jianguo Huang, PhD; Jenna Bailey, BS; Cyr C. De Imus, BS; Stephanie E. Busch, PhD; Teresa Foy, PhD; Pallavur Sivakumar, PhD; Ruth A. Salmon, PhD; Cédric Cleyrat, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor microenvironment | |
201 | Poster Presentation | BNT221, an autologous neoantigen-specific T-cell product for adoptive cell therapy of metastatic ovarian cancer | Christina Arieta, PhD; Diana Velez, MS; Susan B. Hannes, BS; Shirisha Meda, MS; Brian McCarthy; Divya R. Lenkala, MS; Dewi Harjanto; Prerna Suri; Jessica Kohler, PhD; Jonathan McGee; Daniel Kallin; Paul Turcott; Cynthia Nijenhuis; Maarje W. Rohaan; Gabe Sonke; John B. Haanen, MD; Mark DeMario, MD; Richard B. Gaynor, MD; Marit M. Van Buuren, PhD | Cellular Therapies | Adoptive immunotherapy;Neoantigens;RNA;T cell | |
202 | Poster Presentation | In vivo and in vitro characterization of AIM ACT, a novel nanoparticle-based technology, expanded MART-1 specific T cells | Ruipeng Wang, PhD; Lauren Suarez, PhD; Emily Lu, PhD; Pratima Kunwar, PhD; Daniel Dembrow; Sojung Kim, PhD; Mathias Oelke, PhD | Cellular Therapies | Antigen presenting cells;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
203 | Poster Presentation | A Membrane-Tethered IL-15/IL-15 Receptor Fusion Protein Enhances the Persistence and Efficacy of CD70-Targeted TRuC-T Cells | Jian Ding, PhD; Lindsay Webb; Troy Patterson; Michelle Fleury, PhD; Adam Zieba, MS; Holly Horton, PhD; Robert Hofmeister, PhD; Dario Gutierrez; Robert Tighe, NN | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
204 | Poster Presentation | KSQ-004: Unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors | Karrie K. Wong, PhD; Christopher Wrocklage; Sharon Lin, PhD; Isabelle Le Mercier, PhD; Caroline Bullock; Louise Cadzow; Anja Hohmann, PhD; Sol Shenker, PhD; Katri Sofjan; Leila Williams; Gregory Kryukov, PhD; Conor Calnan; Frank Stegmeier, PhD; Micah J. Benson, PhD; Michael Schlabach, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
205 | Poster Presentation | agenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models | Burcu Yigit, PhD; Darrian Moskowitz; Xavier Michelet, PhD; Antoine Tanne, PhD; Marc A. Van Dijk, PhD | Cellular Therapies | Adoptive immunotherapy;Leukemia/Lymphoma;NK/NKT cell;Solid tumors;T cell | |
206 | Poster Presentation | The development of 'chimeric CD3e fusion protein' and 'anti-CD3-based bispecific T cell activating element' engineered T (CAB-T) cells for the treatment of solid malignancies | Andy Tsun, PhD; Zhiyuan Li; Zhenqing Zhang; Weifeng Huang; Shaogang Peng; Jitian Chai | Cellular Therapies | Antibody;Bispecifics;CAR T cells;Costimulation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
207 | Poster Presentation | Enhanced antigen capture, antigen-presenting cell (APC)-like function, and cytotoxic responses with chimeric engulfment receptor (CER) T cells | Daniel Corey, MD; Sunil Thomas, PhD; Brandon Cieniewicz, PhD; Linh Nguyen, PhD; Jared Clever, PhD; Josephine Brysting, BS; Remus Vezan, MD PhD; John M. Rossi, MS; Kurt Diem, PhD; Lei Jin, PhD; Lawrence Corey, MD | Cellular Therapies | Adoptive immunotherapy;Antigen presenting cells;CAR T cells;Costimulation;Dendritic cell;Leukemia/Lymphoma;Monocyte/Macrophage;T cell;TLR;Tumor evasion | |
208 | Poster Presentation | RTX-224, An Engineered Allogeneic Red Cell Therapeutic Expressing 4-1BBL and IL-12, Activates Immune Cells in Blood and Spleen to Promote Tumor Growth Inhibition in Mice | Anne-Sophie Dugast, PhD; Shannon L. McArdel; Zafira Castano; Maegan E. Hoover; Arjun Reddy Bollampalli; Enping Hong; Shannon Leonard; Ryan Pepi; Alex Nanna; Laurence A. Turka; Sivan Elloul | Cellular Therapies | Costimulation;Cytokine;Monocyte/Macrophage;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs) | |
209 | Oral Presentation | Genetically Engineered Myeloid Cells (GEMys) as a Platform to Enhance Antitumor Immunity | Sabina Kaczanowska, PhD; Daniel Beury, PhD; Haiying Qin, MS; Rosandra N. Kaplan, MD | Cellular Therapies | Adoptive immunotherapy;Cytokine;Immune suppression;Monocyte/Macrophage;Myeloid cells;Pediatric tumors;Solid tumors;Tumor microenvironment | |
210 | Poster Presentation | A novel medium for increased cytotoxicity and serum-minimal ex vivo expansion of natural killer (NK) cellular immunotherapies | Marc A. Gillig, PhD; Graeme Lambert; Donna Sonntag; Rachit Ohri, Ph.D.; Jason G. Cahoon, BS; Avishai Shemesh, PhD; Nadhim A. Mukhaiter, MS | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell | |
211 | Poster Presentation | SQZ™ eAPCs generated from PBMCs by delivery of multiple mRNAs encoding for antigens, costimulatory proteins, and engineered cytokines | Michael F. Maloney, PhD; Emrah Ilker Ozay, PhD; Amy Merino; Andrea A. Silva; Amber M. Martin, MS; Sanjana Manja, MS; Madhav Upadhyay, MS; Christine Trumpfheller, PhD; Pablo Umana, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Scott M. Loughhead, PhD | Cellular Therapies | Antigen presenting cells;Costimulation;Cytokine;RNA;Solid tumors;T cell;Tumor antigens;Vaccine | |
212 | Poster Presentation | Tumor adjacent cytokine factories for eradication of ovarian cancer tumor burden in mice through cytotoxic T-cell activation with safe and predictable dosing in non-human primates | Amanda Nash; Maria Jarvis, PhD; Samira Aghlara-Fotovat; Sudip Mukherjee, PhD; Andrea Hernandez; Andrew Hecht; Peter Rios, PhD; Sofia Ghani; Ira Joshi; Douglas Isa; Yufei Cui; Shirin Nouraein; Jared Lee; Chunyu Xu; David Zhang, PhD; Rahul Sheth, MD; Weiyi Peng, PhD; Jose Oberholzer, MD; Oleg Igoshin, PhD; Amir Jazaeri, MD; Omid Veiseh, PhD | Cellular Therapies | Cytokine;Immune toxicity;Inflammation;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
213 | Poster Presentation | AB-X integrated circuit T cells demonstrate improved potency, expansion, and specificity compared to MSLN CAR T cells | Stephen Santoro, PhD; Aaron Cooper, PhD; Natalie Bezman, PhD; Jun Feng, PhD; Kanika Chawla, PhD; Jaspar Williams, PhD; John Gagnon, PhD; Jason Hall, PhD; Dina Polyak, PhD; Angela Boroughs, PhD; Michelle Nguyen; Suchismita Mohanty, PhD; Adam Litterman, PhD; Jeff Granja; David DeTomaso, PhD; Grace Zheng, PhD; Jenessa Smith, PhD; Drake LeFace, PhD; Tarjei Mikkelsen, PhD; Susie Jun, MD, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor microenvironment | |
214 | Poster Presentation | SIRPα-deficient macrophages activate polyclonal tissue-resident cytotoxic CD8 T cells to eliminate irradiation-refractory non-small cell lung carcinoma | Zhen Bian, PhD; Lei Shi, PhD; Koby Kidder, PhD; Yuan Liu, MD PhD | Cellular Therapies | Antigen presenting cells;Immune suppression;Monocyte/Macrophage;Myeloid cells;Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
215 | Poster Presentation | Tissue-resident natural killer cells resembling intraepithelial ILC1 have potent anti-tumor activity in human head and neck cancer and represent a novel class of effector cells for immunotherapy | JuneHo JS. Shin, Ph; Nina B. Horowitz, MS; Quan L. Tran; Chen Chen; Uriel Y. Moreno-Nieves, PhD; Joshua K. Tay, MD PhD; Saumyaa Saumyaa; John B. Sunwoo, MD | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
216 | Oral Presentation | Multiplex base editing of NK cell to enhance cancer immunotherapy | Minjing Wang, BSc; Mitchell G. Kluesner, BSc; Patricia N. Claudio Vázquez, BSc; Beau R. Webber, PhD; Branden S. Moriarity, PhD | Cellular Therapies | Gene expression;NK/NKT cell | |
217 | Poster Presentation | Cytotoxicity of nicotinamide enhanced natural killer cells GDA201 is based on metabolic modulation as demonstrated by artificial intelligence assisted analysis of NK cell transcriptome and metabolome | Dima DY. Yackoubov, MSc; Aviad Pato; Julia Rifman, PhD; Sherri Cohen; Astar Hailu; Nurit Brycman; Orit Berhani-Zipori, PhD; Avishay Edri, PhD; Boaz Buhandler; Moshe Shahor; Nathan Dinowitz; Amram Ben David; Avi Izraeli; Vered Chalifa-Caspi, PhD; Liron Levin, PhD; Joshua D. Rabinowitz, Prof.; Wenyun Lu, PhD; Tracey Lodie, PhD; Julian Adams, PhD; Yona Geffen, PhD | Cellular Therapies | Adoptive immunotherapy;Bioinformatics;Biomarkers;Gene expression;Leukemia/Lymphoma;Metabolism;NK/NKT cell;Proteomics | |
218 | Poster Presentation | Autologous glioblastoma tumor cells and an antisense oligonucleotide against insulin-like growth factor type 1 receptor protect against tumor challenge and generate T cell anti-tumor responses | Jenny Zilberberg, Ph.D.; Amelia Zellander, Ph.D.; Kenneth Kirby, M.S.; Christopher Uhl, Ph.D.; Christopher Cultrara, Ph.D.; Charles Scott, Ph.D.; David Andrews, M.D.; Mark Exley, Ph.D.; Mark Exley, MS, Ph.D. | Cellular Therapies | Cytokine;Immune adjuvant;T cell;Tumor antigens;Vaccine | |
219 | Poster Presentation | CD47 and phosphatidylserine contribute to the interaction between antigen presenting cells and the allogeneic cell-based relapse vaccine DCP-001 | Haoxiao Zuo; Satwinder Kaur Singh, PhD; Marie-José Van Lierop; Jorn Kaspers; Remco Bos; Alwin Kamermans; Helga E. de Vries; Tanja D. de Gruijl, PhD; Ada M. Kruisbeek, PhD; Erik Manting | Cellular Therapies | Antigen presenting cells;Chemokine;Cytokine;Dendritic cell;Immune adjuvant;Leukemia/Lymphoma;Monocyte/Macrophage;Myeloid cells;Tumor antigens;Vaccine | |
220 | Poster Presentation | Transfection of human adipose-derived mast cells: A characteristic study using different chemical reagents | Mona Motaghed, PhD Candidate; Christopher Kepley, Ph.D.; Kristen Dellinger, Ph.D.; Elnaz Ahani, Ph.D. Candidate; Mohammad Fereydouni, Ph.D. Candidate | Cellular Therapies | Adoptive immunotherapy;Gene expression;Monocyte/Macrophage | |
221 | Oral Presentation | CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors | Rebecca C. Larson, BS; Michael Kann; Stefanie R. Bailey, PhD; Nicholas J. Haradhvala; Kai Stewart; Amanda Bouffard; Irene Scarfo; Mark Leick; Trisha R. Berger; Max Jan; Julia Joung; Tamara Ouspenskaia; Travis Law; Aviv Regev, PhD; Gad Getz, PhD; Marcela V. Maus, MD, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;Solid tumors | |
222 | Poster Presentation | Genetic reprogramming of Merkel cell carcinoma and melanoma leads to increased MHC-I expression and antitumor immune activation in vitro and in vivo | Kathryn M. Luly, BS; Jordan J. Green, PhD; Stephany Y. Tzeng, PhD; Joel C. Sunshine, MD, PhD | Cellular Therapies | Costimulation;Cytokine;Immune adjuvant;NK/NKT cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
223 | Poster Presentation | Potent inhibition of PI3Kδ promotes enhanced T cell stemness and mitochondrial fitness | Guillermo O. Rangel RIvera, B.S.; Connor J. Dwyer, PhD; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Anna C. Cole, BA; Megan M. Wyatt, MS; Brandon Ware, PhD; Chrystal M. Paulos, PhD | Cellular Therapies | Adoptive immunotherapy;Immune adjuvant;Metabolism;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) | |
224 | Poster Presentation | M2 macrophage-mediated immune suppression of chimeric antigen receptor T cells via PD-L1 signaling in prostate cancer | Yukiko Yamaguchi; Jackson Gibson; Kevin Ou; Saul Priceman, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors | |
225 | Poster Presentation | Optimal-affinity MAGE-A1-specific T cell receptors (TCRs) generated using the humanized TCR-transgenic mouse platform HuTCR are superior to human donor-derived TCRs | Ioannis IG. Gavvovidis, PhD; Matthias Leisegang, Prof. Dr.; Vivian Scheuplein, PhD; Matthias Obenaus, MD; Thomas Blankenstein, PhD; Elisa Kieback, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
226 | Poster Presentation | Neoantigen-specific TCR-T cells targeting shared hotspot mutations for adoptive cell therapy in common epithelial cancers | Ana B. Korngold, PhD; Jean Lin-Kin Yong, PhD; Ugochi C. Ibekwe; Julissa Simmons; Phillip Eckels, MPH; Elizabeth Figueroa, PhD; Michelle Hotard; Frances Adeyemi; Thomas Hunt; Tegan Markus; Lenka V. Hurton, PhD; Yaoyao Shi, PhD; Matthew R. Collinson-Pautz, PhD; Priya Balasubramanian, PhD; Cathy Wang, PhD; Jourdan Andersson, PhD; Lauren Heese; Mariam Khalil; David Torres; Emarco Olivares; Geraldine Bardelli; Kelly O'Brien, PhD; Haroon Hashmi; Alena Chekmasova; Raffaele Baffa, MD; Tom Spencer, PhD; Eleanor De Groot, PhD; Drew C. Deniger, PhD | Cellular Therapies | Adoptive immunotherapy;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor antigens | |
Late-Breaking | ||||||
946 | Poster Presentation | Standardized transcriptional profiling for optimizing cellular therapies: A Multi-Center PICI-NanoString collaboration | Sarah E. Church, PhD; Christina M. Bailey, MS; Sarah E. Warren, PhD; Lisa H. Butterfield, PhD; | Cellular Therapies | RNA;Adoptive immunotherapy;Bioinformatics;Biomarkers;CAR T cells;Gene expression;Immune monitoring;Immune toxicity;Leukemia/Lymphoma;Solid tumors |